Bausch Health Companies Inc. (BHC)

CA — Healthcare Sector
Peers: HCM  PRGO  CON  XRAY  ALVO  CPRX  HAE  ANIP  BEAM  MLYS 

Automate Your Wheel Strategy on BHC

With Tiblio's Option Bot, you can configure your own wheel strategy including BHC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BHC
  • Rev/Share 22.2702
  • Book/Share 0.9598
  • PB -4.628
  • Debt/Equity -37.2062
  • CurrentRatio 1.3038
  • ROIC 0.0515

 

  • MktCap 2612144328.0
  • FreeCF/Share 2.9496
  • PFCF 2.3877
  • PE 7.2233
  • Debt/Assets 0.7837
  • DivYield 0
  • ROE -0.382

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
BHC
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral

LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.

Read More
image for news Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
BHC
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral

Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B …

Read More
image for news Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
BHC
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral

LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.

Read More
image for news Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
BHC
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral

LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P.

Read More
image for news Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
BHC
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive

Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment.

Read More
image for news Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
BHC
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

Read More
image for news Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics
BHC
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
BHC
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call.

Read More
image for news Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
BHC
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago.

Read More
image for news Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
BHC
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24.

Read More
image for news Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More
BHC
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth

Read More
image for news Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More

About Bausch Health Companies Inc. (BHC)

  • IPO Date 1994-03-29
  • Website https://www.bauschhealth.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Thomas J. Appio
  • Employees 20700

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.